Grant ID

97-RC-299-10

Illness

Bipolar Disorder

Primary Drug/Intervention

Triacetyluridine

Primary Dosage

N/A

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Cohen

Sample Size

20

Duration of Study Period for Each Subject

N/A

Outcome Measurements

N/A

Results

Ten patients with bipolar disorder received triacetyluridine in an open label design for 6 weeks. Seven of the 10 patients were considered to be responders.

Publication

N/A

Link

N/A

PI Name

Bruce Cohen

Degree

MD

Center

N/A

Institution

N/A

Address

City or Town

Belmont

State or Province

MA

Zip or Postal Code

N/A

Country

USA

Email Address

cohenb@mclean.harvard.edu